Agalsidase alfa therapy for Fabry disease

Area of Science:

• Genetics
• Biochemistry
• Medicine

Background:

• Fabry disease is a genetic lysosomal storage disorder caused by mutations in the GLA gene.
• This genetic defect leads to a deficiency in the enzyme α-galactosidase A.
• The enzyme deficiency results in the harmful accumulation of glycosphingolipids in various tissues.

Purpose of the Study:

• To evaluate the efficacy of recombinant human agalsidase alfa as an enzyme replacement therapy for Fabry disease.
• To assess the impact of this therapy on key clinical manifestations including pain, renal function, and cardiac hypertrophy.

Main Methods:

• Administration of recombinant human agalsidase alfa to patients with Fabry disease.
• Monitoring of clinical outcomes such as neuropathic pain, renal function parameters, and cardiac hypertrophy.

Main Results:

• Preliminary data indicate that agalsidase alfa therapy can improve neuropathic pain in patients.
• The therapy shows potential in stabilizing progressive renal dysfunction.
• Improvements in cardiac hypertrophy have been observed in some treated individuals.

Conclusions:

• Recombinant human agalsidase alfa represents a potential therapeutic option for managing Fabry disease symptoms.
• While promising for pain, renal, and cardiac aspects, more extensive data are required.
• Further studies must investigate the long-term efficacy of agalsidase alfa in preventing severe outcomes like stroke, cardiac events, and mortality.